Geneuro AAQS 2024

Hvad gør Geneuro?

Geneuro SA is a biopharmaceutical company based in Plan-les-Ouates, Geneva, Switzerland. It was founded in 2007 and focuses on the development of innovative therapies for autoimmune diseases and other neurological disorders. Geneuro was founded based on research by Prof. Jean-Michel Goust, a renowned pain therapist and neuroimmunologist. In collaboration with distinguished scientists and experts in the field of neuroimmunology and neurovirology, he developed a new concept for combating autoimmune diseases of the nervous system, such as multiple sclerosis. Geneuro's business model is centered around developing novel therapeutics for chronic neurological disorders, particularly through immunomodulation. The drugs aim to help regulate the body's immune system to suppress inflammatory reactions in the brain, thereby preventing or at least reducing the adverse effects of autoimmune diseases. The company divides its activities into two main areas: research and development of novel therapeutics, and marketing of products. In the research and development field, Geneuro works closely with various partners such as universities, research institutes, and other companies. The aim is to translate the latest scientific knowledge in the fields of neuroimmunology and neurovirology into clinical practice in order to provide patients with better treatment options. Geneuro has focused on a specific class of drugs known as "anti-HERV," which stands for "human endogenous retroviruses." These retroviral particles make up approximately five percent of the human genome and are currently an active research area in neuroimmunology. Geneuro has developed a method to produce specific antibodies against these retroviruses and utilizes these antibodies as therapeutics in the fight against autoimmune diseases. The leading product of Geneuro in this area is GNbAC1, a novel monoclonal antibody preparation against the HERV virus, which was developed in collaboration with Merck Serono. GNbAC1 is currently in the clinical testing phase (Phase III) and has already shown promising results. It demonstrates significant efficacy in the treatment of multiple sclerosis and is also being tested for the treatment of other neuroimmunological diseases such as neuromyelitis optica and amyotrophic lateral sclerosis. In addition to GNbAC1, Geneuro has other products in the development phase. These include GNbAC2, a product specifically developed for the Japanese market in collaboration with Toyama Chemical Co., Ltd., and GNbAC-K9, a product for dogs designed to treat degenerative central nervous system disorders. Geneuro's second business area involves the marketing of its products. The company collaborates with both large pharmaceutical companies and smaller biotech companies worldwide to broaden the reach of their products. In recent years, Geneuro has established itself as a significant player in the field of neurological disorders. The company has developed promising therapies for autoimmune diseases that regulate the body's immune system in an innovative way. Geneuro's antibody preparations aim to target a specific class of proteins to contain inflammation in the brain and achieve broader efficacy in the treatment of neurological diseases such as MS. The company has set ambitious goals to improve its products and enhance its innovation capabilities, and will continue to drive significant developments in the future. Geneuro ist eines der beliebtesten Unternehmen auf Eulerpool.com.